

# David Sim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11222787/publications.pdf>

Version: 2024-02-01

52  
papers

5,073  
citations

257450

24  
h-index

182427

51  
g-index

52  
all docs

52  
docs citations

52  
times ranked

4782  
citing authors

#	ARTICLE	IF	CITATIONS
1	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2021, 385, 1451-1461.	27.0	2,143
2	Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. <i>Lancet</i> , The, 2020, 396, 1895-1904.	13.7	425
3	Right ventricular dysfunction in left-sided heart failure with preserved versus reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2017, 19, 1664-1671.	7.1	224
4	Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1279-1287.	7.1	205
5	Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study. <i>European Heart Journal</i> , 2018, 39, 1770-1780.	2.2	194
6	Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2012, 14, 1338-1347.	7.1	181
7	Circulating microRNAs in heart failure with reduced and preserved left ventricular ejection fraction. <i>European Journal of Heart Failure</i> , 2015, 17, 393-404.	7.1	160
8	Angiotensin Receptor-Nepilysin Inhibition in Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2021, 385, 1845-1855.	27.0	130
9	Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2016, 18, 81-88.	7.1	128
10	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2018, 11, e004962.	3.9	117
11	Iron deficiency in a multi-ethnic Asian population with and without heart failure: prevalence, clinical correlates, functional significance and prognosis. <i>European Journal of Heart Failure</i> , 2014, 16, 1125-1132.	7.1	104
12	Heart failure across Asia: Same healthcare burden but differences in organization of care. <i>International Journal of Cardiology</i> , 2016, 223, 163-167.	1.7	101
13	Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. <i>European Journal of Heart Failure</i> , 2020, 22, 2383-2392.	7.1	93
14	The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2017, 19, 1638-1647.	7.1	74
15	Understanding the Epidemiology of Heart Failure to Improve Management Practices: An Asia-Pacific Perspective. <i>Journal of Cardiac Failure</i> , 2017, 23, 327-339.	1.7	72
16	The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. <i>European Heart Journal</i> , 2021, 42, 3011-3020.	2.2	71
17	Combining Circulating MicroRNA and NT-proBNP to Detect and Categorize Heart Failure Subtypes. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1300-1313.	2.8	68
18	The Singapore Heart Failure Outcomes and Phenotypes (SHOP) Study and Prospective Evaluation of Outcome in Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction (PEOPLE) Study: Rationale and Design. <i>Journal of Cardiac Failure</i> , 2013, 19, 156-162.	1.7	61

#	ARTICLE	IF	CITATIONS
19	Prevalence and Clinical Significance of Diabetes in Asian Versus White Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 14-24.	4.1	57
20	Rationale and design of the AFFIRM-CHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 1651-1658.	7.1	42
21	Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 4442-4451.	2.2	38
22	The Optimize Heart Failure Care Program: Initial lessons from global implementation. <i>International Journal of Cardiology</i> , 2017, 236, 340-344.	1.7	29
23	Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. <i>Circulation</i> , 2022, 145, 87-89.	1.6	28
24	Predictors of two-year mortality in Asian patients with heart failure and preserved ejection fraction. <i>International Journal of Cardiology</i> , 2015, 183, 33-38.	1.7	27
25	Impact of a Formal Advance Care Planning Program on End-of-Life Care for Patients With Heart Failure: Results From a Randomized Controlled Trial. <i>Journal of Cardiac Failure</i> , 2020, 26, 594-598.	1.7	25
26	Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction. <i>Journal of Medical Economics</i> , 2018, 21, 174-181.	2.1	24
27	Ethnic differences in atrial fibrillation in patients with heart failure from Asia-Pacific. <i>Heart</i> , 2019, 105, 842-847.	2.9	22
28	Impact of change in iron status over time on clinical outcomes in heart failure according to ejection fraction phenotype. <i>ESC Heart Failure</i> , 2021, 8, 4572-4583.	3.1	21
29	Predictors of mortality in acute heart failure: interaction between diabetes and impaired left ventricular ejection fraction. <i>European Journal of Heart Failure</i> , 2014, 16, 1183-1189.	7.1	17
30	Cognitive impairment in Asian patients with heart failure: prevalence, biomarkers, clinical correlates, and outcomes. <i>European Journal of Heart Failure</i> , 2019, 21, 688-690.	7.1	16
31	Ethnic differences in the association of QRS duration with ejection fraction and outcome in heart failure. <i>Heart</i> , 2016, 102, 1464-1471.	2.9	15
32	Defining a "frequent admitter" phenotype among patients with repeat heart failure admissions. <i>European Journal of Heart Failure</i> , 2019, 21, 311-318.	7.1	15
33	Heart failure with preserved ejection fraction diagnostic scores in an Asian population. <i>European Journal of Heart Failure</i> , 2020, 22, 1737-1739.	7.1	14
34	Instability in End-of-Life Care Preference Among Heart Failure Patients: Secondary Analysis of a Randomized Controlled Trial in Singapore. <i>Journal of General Internal Medicine</i> , 2020, 35, 2010-2016.	2.6	14
35	Patient barriers to implantable cardioverter defibrillator implantation for the primary prevention of sudden cardiac death in patients with heart failure and reduced ejection fraction. <i>Singapore Medical Journal</i> , 2016, 57, 182-187.	0.6	14
36	Prediction of Survival in Asian Patients Hospitalized With Heart Failure: Validation of the OPTIMIZE-HF Risk Score. <i>Journal of Cardiac Failure</i> , 2019, 25, 571-575.	1.7	13

#	ARTICLE	IF	CITATIONS
37	Atrial Fibrillation and the Prognostic Performance of Biomarkers in Heart Failure. <i>Clinical Chemistry</i> , 2021, 67, 216-226.	3.2	13
38	Instability in Preference for Place of Death Among Patients With Symptoms of Advanced Heart Failure. <i>Journal of the American Medical Directors Association</i> , 2021, 22, 349.e29-349.e34.	2.5	13
39	Thymosin Beta $\alpha$ 4 Is Elevated in Women With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	12
40	Cornell product is an ECG marker of heart failure with preserved ejection fraction. <i>Heart Asia</i> , 2019, 11, e011108.	1.1	9
41	N $\alpha$ -terminal pro $\beta$ -type natriuretic peptide and prognosis in <sc>Caucasian</sc> vs. <sc>Asian</sc> patients with heart failure. <i>ESC Heart Failure</i> , 2018, 5, 279-287.	3.1	8
42	Ethnic differences in quality of life and its association with survival in patients with heart failure. <i>Clinical Cardiology</i> , 2020, 43, 976-985.	1.8	8
43	Impact Of Sex On Clinical Characteristics And In-Hospital Outcomes In A Multi-Ethnic Southeast Asian Population Of Patients Hospitalized For Acute Heart Failure. <i>ASEAN Heart Journal: Official Journal of the ASEAN Federation of Cardiology</i> , 2014, 22, 8.	0.0	6
44	Risk stratification of Asian patients with heart failure and reduced ejection fraction: the effectiveness of the Echo Heart Failure Score. <i>European Journal of Heart Failure</i> , 2017, 19, 1732-1735.	7.1	6
45	Financial difficulties and patient-reported outcomes among patients with advanced heart failure. <i>Quality of Life Research</i> , 2021, 30, 1379-1387.	3.1	5
46	Supporting the Management of Patients with Heart Failure within Asia-Pacific, Middle East, and African Countries: A Toolbox for Healthcare Providers. <i>Cardiology</i> , 2019, 142, 1-10.	1.4	4
47	Age and ejection fraction modify the impact of atrial fibrillation on acute heart failure outcomes. <i>European Journal of Heart Failure</i> , 2018, 20, 821-822.	7.1	2
48	Mortality outcome and predictive risk factors for death in patients with heart failure and reduced ejection fraction who declined implantable cardioverter defibrillator implantation in Singapore. <i>Journal of Arrhythmia</i> , 2018, 34, 536-540.	1.2	2
49	Left Ventricular Diastolic Function Assessment Using Time Differences Between Mitral Annular Velocities and Transmitral Inflow Velocities in Patients with Heart Failure. <i>Heart Lung and Circulation</i> , 2015, 24, 257-263.	0.4	1
50	Reply: Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction. <i>Journal of Medical Economics</i> , 2018, 21, 1148-1149.	2.1	1
51	QRS duration and cardiovascular mortality in Asian patients with heart failure and preserved and reduced ejection fraction. <i>Cardiology Journal</i> , 2021, 28, 166-169.	1.2	1
52	Angiotensin receptor-neprilysin inhibitor improves New York Heart Association class and N-terminal-pro B-type natriuretic peptide levels: initial experience in a Singapore single-centre cohort. <i>Singapore Medical Journal</i> , 2021, 62, 359-361.	0.6	0